Risk communication strategy
This article was originally published in The Tan Sheet
Executive Summary
FDA says the Risk Communication Advisory Committee will discuss the draft strategic plan and offer further advice on priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. At its previous meeting, the committee emphasized the need for FDA to assess the effectiveness of its communications as a part of ensuring safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)
You may also be interested in...
FDA Risk Communication Research May Follow Critical Path To Avoid OMB
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.